Goldman Sachs Maintains Buy Rating on Humana

A report from Goldman Sachs reiterates its Buy rating on Humana HUM. The report states, “As expected, 3Q upside was driven primarily by a continuation of favorable medical cost trends. The consolidated medical cost ratio (MCR) was 80.7% vs. our 82.5%, partly offset by a consolidated OCR (operating cost ratio) of 14.8% vs. our 14.6%. Enrollment was in line or ahead of our model as were both premium (+1% vs. our model) and (+3% vs. our model) fee revenues." HUM closed Friday at $80.35.